Puma Biotech cleared to trial Takeda-partnered breast cancer therapy in U.S. [Seeking Alpha]
Puma Biotechnology Inc (PBYI)
Last puma biotechnology inc earnings: 2/20 04:07 pm
Check Earnings Report
US:NYSE Investor Relations:
pumabiotechnology.com/ir.html
Company Research
Source: Seeking Alpha
alisertib, in-licensed from Takeda ( NYSE: TAK ), in patients with breast cancer. The study named ALISCA-Breast1 is designed to evaluate alisertib in combination with endocrine therapy in patients with hormone receptor-positive, HER2-negative recurrent, or metastatic breast cancer who hadn't undergone chemotherapy. According to the company's Investigational New Drug Application (IND), the trial will be designed to evaluate the therapeutic combo as a late-line option for the patient group. Puma Biotechnology ( PBYI ) plans to start ALISCA-Breast1 in H2 2024. In September 2022, Takeda ( TAK ) outlicensed alisertib, an inhibitor of aurora kinase A, to PBYI in a deal worth $7M upfront and $287.3M in potential milestone payments. Recommended For You More Trending News Recommended For You More Trending News Related Stocks In The News Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
PBYI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PBYI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PBYI alerts
High impacting Puma Biotechnology Inc news events
Weekly update
A roundup of the hottest topics
PBYI
News
- What's in Store for Puma Biotechnology (PBYI) in Q1 Earnings? [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial ResultsBusiness Wire
- Puma Biotech (PBYI) Stock Dips While Market Gains: Key Facts [Yahoo! Finance]Yahoo! Finance
- Puma Biotechnology, Inc. (NASDAQ: PBYI) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Puma Biotechnology (NASDAQ:PBYI) shareholders have earned a 93% return over the last year [Yahoo! Finance]Yahoo! Finance
PBYI
Earnings
- 2/29/24 - Miss
PBYI
Analyst Actions
- 2/13/24 - HC Wainwright
PBYI
Sec Filings
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form ARS
- 4/26/24 - Form DEF
- PBYI's page on the SEC website